Datavault AI Expands DataMEDS Deal Into Commercial Healthcare, Takes 19.9% Equity Stake
DVLT sits 29% above its 52-week low of $0.251 on light trading volume (0.2× avg).
Summary
Datavault AI expanded its licensing agreement with DataMEDS AI, moving its PharmacyChain blockchain technology into commercial healthcare, healthspan, and wellness. The deal now gives Datavault a 19.9% common equity stake in DataMEDS upon closing of previously announced transactions, replacing preferred shares for tax optimization. This follows a series of aggressive moves by Datavault, including a $2B structured financing term sheet in June and a $50M Bitcoin sale to Scilex. The expansion targets patient-controlled health data monetization and real-world asset tokenization, potentially opening a new revenue stream in the large healthcare market. With a market cap around $277M and a stock price near $0.32, the equity stake could become a meaningful asset if DataMEDS gains traction. Watch for closing of the related transactions and any financial details on the DataMEDS stake valuation.
At the time of this announcement, DVLT was trading at $0.32 on NASDAQ in the Technology sector, with a market capitalization of approximately $277.1M. The 52-week trading range was $0.25 to $4.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.